Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13038941 | 0.83 | NLRP3 (0.42) | TMEM97SIGMAR1KMT2AMAPTKDM4E | |
| SCHEMBL4075540 | 0.77 | ADAMTS5 (0.38) | KMT2APTK2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3546618 | 0.74 | MAPT (0.55) | KMT2AMAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL2370707 | 0.71 | NPC1 (0.56) | CHKAKMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL25822408 | 0.70 | ALDH1A1 (0.36) | CYP11B2KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL3549535 | 0.69 | SIRT6 (0.62) | MAPTALDH1A1MAPK1 | |
| SCHEMBL3547211 | 0.69 | HDAC3 (0.44) | KMT2APTK2MAPTKDM4EALDH1A1 | |
| SCHEMBL989799 | 0.68 | SIRT6 (0.41) | CYP11B2PTK2MAPTALDH1A1LMNA | |
| SCHEMBL1996163 | 0.68 | HTR2C (0.41) | HRH4KDM4EALDH1A1HSD17B10 | |
| SCHEMBL5790195 | 0.67 | AGXT (0.61) | TMEM97SIGMAR1NPC1ADRA2CRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825124-B2 | Indolylmaleimide derivatives | ALBERT RAINER | 2010-11-02 | — | — | US | disclosed |
| US-7786123-B2 | Indolylmaleimide derivatives | ALBERT RAINER | 2010-08-31 | — | — | US | disclosed |
| US-20090318463-A1 | Indolylmaleimide Derivatives | ALBERT RAINER | 2009-12-24 | — | — | US | disclosed |
| EP-1337527-B1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-2070921-A1 | Indolylmaleimide derivatives as protein kinase c inhibitors | Novartis Ag (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | ALBERT RAINER | 2007-08-16 | — | — | US | disclosed |
| US-20070184061-A1 | Indolylmaleimide derivatives | ALBERT RAINER | 2007-08-09 | — | — | US | disclosed |
| US-20070155817-A1 | Indolylmaleimide derivatives | ALBERT RAINER | 2007-07-05 | — | — | US | disclosed |
| US-7220774-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2007-05-22 | — | — | US | disclosed |
| US-20040053949-A1 | Indolylmaleimide derivatives | ALBERT RAINER (CH) | 2004-03-18 | — | — | US | disclosed |
| US-6645970-B2 | Preventing T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer | NOVARTIS AG (CH) | 2003-11-11 | — | — | US | disclosed |
| EP-1337527-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | Novartis AG (CH) | 2003-08-27 | — | — | EP | disclosed |
| US-20030069424-A1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2003-04-10 | — | — | US | disclosed |
| WO-2002038561-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318463-A1 | Indolylmaleimide Derivatives | NFATC1, INMT, IDO1 | CYP11B2 1439/4885CHKA 1719/4885TMEM97 4624/4885 |
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | NFATC1, HLA-DRB1, INMT | CYP11B2 1841/4885CHKA 3159/4885TMEM97 4191/4885 |
| US-20030069424-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | CYP11B2 1439/4885CHKA 1719/4885TMEM97 4624/4885 |
| US-20040053949-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | CYP11B2 1439/4885CHKA 1719/4885TMEM97 4624/4885 |
| US-20070155817-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | CYP11B2 1439/4885CHKA 1719/4885TMEM97 4624/4885 |
| US-20070184061-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | CYP11B2 1439/4885CHKA 1719/4885TMEM97 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.